2 January 2025 - Patients for whom cisplatin-based therapy is unsuitable live significantly longer with the new combination of active ingredients than with previous treatment options.

Enfortumab vedotin has been approved for the treatment of previously treated adults with locally advanced or metastatic urothelial carcinoma since April 2022. Since September 2024, enfortumab vedotin in combination with pembrolizumab has also been approved for the first-line treatment of inoperable or metastatic urothelial carcinoma. In a benefit assessment, the IQWiG has now investigated whether the combination offers these patients additional benefit compared to previous standard therapy.

Read IQWiG press release